Our Market

Molecular Imaging Market

FluoroPharma’s products utilize positron emission tomography (PET) technology, a molecular imaging platform that is growing rapidly due to its inherently superior sensitivity and specificity compared to other imaging options. Molecular imaging fulfills unmet needs in diagnosis and follow-up therapy by enabling visualization, characterization and measurement of biological processes at the molecular and cellular level. Unlike more commonly known imaging modalities - MRI, CT, and Ultrasound - that provide insight into the anatomical manifestation of disease, molecular imaging techniques, such as PET, provide insight into physiology and can detect disease before anatomical manifestation is identified. Research firm Future Market Insights reported in 2017 that the global Molecular Imaging market could reach $6.4 billion on a robust CAGR of 7.5% (FMI via Globe Newswire, Dec 20, 2017).

Cardiovascular Market 

According to the American Heart Association, an estimated 92.1 million US adults have at least 1 type of cardiovascular disease (CVD). By 2030, 43.9% of the US adult population is projected to have some form of CVD (2017 Heart and Stroke Statistical Update).

From 2004 to 2014, the actual number of CVD deaths decreased 6.7%; a reflection of the benefit of new technology and therapeutics directed toward finding and treating atherosclerosis.

Cardiologists' demand for faster, more accurate diagnostic tools continuously drives the development of non-invasive techniques with increased sensitivity and accuracy for the detection and assessment of acute and chronic forms of CVD. Nuclear Medicine and Molecular imaging are currently used in more than 6 million myocardial perfusion imaging (MPI) procedures, the standard test for diagnosing ischemia related to CVD.